Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15248884 | 1.00 | IDO1 (0.54) | IDO1MAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2576999 | 0.84 | ALDH1A1 (0.55) | MAPTALDH1A1HPGDSMN1; SMN2KMT2A | |
| SCHEMBL30879550 | 0.83 | SLC9A1 (0.62) | IDO1MAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL30879548 | 0.83 | SLC9A1 (0.62) | IDO1MAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5780021 | 0.83 | SLC9A1 (0.62) | IDO1MAPTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL23425327 | 0.81 | MAPT (0.58) | MAPTALDH1A1HPGDSMN1; SMN2NPC1 | |
| SCHEMBL15248885 | 0.81 | MAPT (0.58) | MAPTALDH1A1HPGDSMN1; SMN2NPC1 | |
| SCHEMBL3737728 | 0.81 | MAPT (0.58) | MAPTALDH1A1HPGDSMN1; SMN2NPC1 | |
| SCHEMBL2563497 | 0.81 | MAPT (0.58) | MAPTALDH1A1HPGDSMN1; SMN2NPC1 | |
| SCHEMBL23116564 | 0.81 | MAPT (0.58) | MAPTALDH1A1HPGDSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720036-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | 16380026 Canada Inc. (CA) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024243692-A1 | CYP26B1 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2024-12-05 | — | — | WO | disclosed |
| US-7834013-B2 | Racemic-(trans)-2-[4-({[3-(phenyloxy)phenyl]methyl}ammonium)phenyl]cyclopropanecarboxylic acid; type II diabetes; G protein-coupled receptor 40 (GPR40) agonists | GLAXOSMITHKLINE LLC (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090105257-A1 | AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 | GLAXOSMITHKLINE LLC | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105257-A1 | AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 | GPR65, GPR88, GPR84 | IDO1 3106/4885MAPT 3025/4885ALDH1A1 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.